DYANAVEL XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYANAVEL XR (DYANAVEL XR).
Dyanavel XR is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and increasing their release, thereby enhancing neurotransmission in the brain regions involved in attention and impulse control.
| Metabolism | Primarily metabolized by the liver via deamination and oxidation to form inactive metabolites, including benzoic acid and hippuric acid. The metabolism is not significantly mediated by cytochrome P450 enzymes; however, minor involvement of CYP2D6 has been suggested. |
| Excretion | Approximately 30-50% of a dose is excreted unchanged in urine; remainder as metabolites (primarily hippuric acid) via renal elimination. Fecal excretion is minimal. |
| Half-life | Mean terminal elimination half-life is approximately 8-10 hours for d-amphetamine and 12-14 hours for l-amphetamine; the extended-release formulation maintains therapeutic concentrations for 12-14 hours. |
| Protein binding | Approximately 16-20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 3-4 L/kg for total amphetamine, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability of amphetamine is approximately 90% for the immediate-release formulation; the extended-release formulation (DYANAVEL XR) provides comparable bioavailability with a prolonged absorption phase. |
| Onset of Action | Oral: Onset of clinical effect (improved attention) occurs within 1-2 hours post-dose. |
| Duration of Action | Duration of clinical effect is approximately 12-14 hours based on extended-release profile; once-daily dosing provides symptom control throughout the day. |
Initial dose: 5 mg orally once daily in the morning. Maximum dose: 20 mg once daily. May increase by 5–10 mg weekly based on tolerability and response.
| Dosage form | SUSPENSION, EXTENDED RELEASE |
| Renal impairment | GFR 30–59 mL/min: maximum recommended dose 10 mg once daily. GFR 15–29 mL/min: maximum recommended dose 5 mg once daily. GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh class A (mild): no adjustment necessary. Child-Pugh class B (moderate): maximum recommended dose 10 mg once daily. Child-Pugh class C (severe): not recommended. |
| Pediatric use | Ages 6–12 years: initial dose 5 mg orally once daily; maximum 20 mg once daily. Ages 13–17 years: initial dose 5 mg once daily; maximum 20 mg once daily. Weight-based: no specific weight-based dosing; use lowest effective dose. |
| Geriatric use | Starting dose: 5 mg once daily; increase cautiously. Monitor for cardiovascular effects (hypertension, tachycardia) and cognitive changes. Consider lower maximum dose due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DYANAVEL XR (DYANAVEL XR).
| Breastfeeding | Excreted in breast milk; M/P ratio not established. Potential adverse effects on infant growth and development. American Academy of Pediatrics recommends avoiding use during breastfeeding unless benefit outweighs risk. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show increased incidence of cardiovascular malformations. Second and third trimesters: Risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (tremors, irritability, hypertonia). |
■ FDA Black Box Warning
DYANAVEL XR has a high potential for abuse and dependence. Prolonged use may lead to drug dependence and must be avoided in patients with a history of drug abuse or alcoholism. Careful supervision is required during withdrawal from abusive use because severe depression may occur. Misuse may cause sudden death and serious cardiovascular adverse events.
| Serious Effects |
["Known hypersensitivity to amphetamine or other components of the product","Concurrent use or within 14 days of monoamine oxidase inhibitor (MAOI) therapy","History of drug abuse","Advanced arteriosclerosis","Symptomatic cardiovascular disease","Moderate to severe hypertension","Hyperthyroidism","Glaucoma","Agitated states"]
| Precautions | ["Serious cardiovascular events including sudden death, stroke, and myocardial infarction have been reported in patients with structural cardiac abnormalities or other serious heart problems.","Blood pressure and heart rate should be monitored regularly.","Psychiatric adverse events such as exacerbation of pre-existing psychosis, manic episodes, and aggressive behavior may occur.","Long-term suppression of growth (height and weight) has been observed; monitor growth during treatment.","May cause peripheral vasculopathy including Raynaud's phenomenon.","May lower seizure threshold; use with caution in patients with seizure disorders."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, and signs of stimulant abuse. Fetal ultrasound to assess growth and potential anomalies. Neonatal monitoring for withdrawal symptoms after delivery. |
| Fertility Effects | No formal studies; animal data suggest potential for reduced fertility at high doses. Clinical implications unclear. |